Table 3 Relationship of four classes based on PD-L1 expression and CD8+ TILs
From: Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression
| Subgroup I | Subgroup II | Subgroup III | Subgroup IV | |
|---|---|---|---|---|
|
CD8high PD-L1− |
CD8high PD-L1+ |
CD8low PD-L1− |
CD8low PD-L1+ | |
|
Clinical parameters n (%) | (n = 12) | (n = 21) | (n = 18) | (n = 15) |
| Age median (range) | 65 (50–79) | 64 (29–75) | 66 (48–79) | 70 (45–81) |
| Sex (Female) | 7 (58%) | 12 (57%) | 10 (56%) | 9 (60%) |
| TNM stage (III + IV) | 7 (58%) | 11 (52%) | 14 (78%) | 11 (73%) |
| Risk factors | ||||
| Gallstone | 3 (25%) | 13 (62%) | 11 (61%) | 9 (60%) |
| Diabetes | 4 (33%) | 6 (29%) | 7 (39%) | 3 (20%) |
| Hypertension | 4 (33%) | 8 (38%) | 8 (44%) | 5 (33%) |
| Cholecystitis | 7 (58%) | 12 (57%) | 14 (78%) | 10 (67%) |
| Jaundice | 0 (0%) | 6 (29%) | 4 (22%) | 4 (27%) |
| Completed resection | 8 (67%) | 16 (76%) | 11 (61%) | 11 (73%) |
| CEA (> 5 μg/L) | 2 (17%) | 5 (24%) | 4 (22%) | 9 (60%) |
| CA19–9 (> 34 U/mL) | 4 (33%) | 13 (62%) | 11 (61%) | 7 (58%) |
| Liver dysfunction | ||||
| ALT (> 40 U/L) | ||||
| AST (> 35 U/L) | 1 (8%) | 5 (24%) | 5 (28%) | 4 (27%) |
| TBil (> 22.2 μmol/L) | 3 (25%) | 5 (24%) | 6 (33%) | 5 (33%) |
| DBil (> 6.8 μmol/L) | 3 (25%) | 7 (33%) | 5 (28%) | 5 (33%) |
| GGT (> 45 U/L) | 1 (8%) | 7 (33%) | 5 (28%) | 5 (33%) |
| ALP (> 135 U/L) | 3 (25%) | 7 (33%) | 5 (28%) | 5 (33%) |
| 2 (17%) | 9 (43%) | 5 (28%) | 4 (27%) | |
| Pathological features | ||||
| Differentiation (Poor) | 5 (42%) | 12 (57%) | 9 (50%) | 12 (80%) |
| Tumor size, cm (median, range) | 2.4 (0.6–7.5) | 3.5 (0.5–7.0) | 3.0 (0.6–6.0) | 2.0 (0.8–7.0) |
| Immunohistochemistry | ||||
| CD133+ in TCs, n (%) | 5 (42%) | 9 (43%) | 6 (33%) | 7 (58%) |
| PD-1+ in TILs, n (%) | 7 (58%) | 9 (43%) | 6 (33%) | 11 (73%) |
| PD-L2+ in TCs, n (%) | 5 (42%) | 17 (81%) | 9 (50%) | 13 (87%) |
| CD8+ TILs density | 60.5 | 79 | 28 | 27 |
| (median, range) | (47–167) | (49–275) | (4–42) | (8–46) |
| Adjuvant treatment | ||||
| Chemotherapy, n (%) | 7 (58%) | 12 (57%) | 13 (72%) | 8 (53%) |
| Radiotherapy, n (%) | 2 (17%) | 5 (24%) | 4 (22%) | 4 (27%) |
| Others, n (%) | 3 (25%) | 8 (33%) | 6 (33%) | 4 (27%) |
| No, n (%) | 2 (17%) | 4 (19%) | 2 (11%) | 2 (13%) |
| Palliative treatment at stage IV | ||||
| With therapy, n (%) | 8 (67%) | 16 (76%) | 15 (83%) | 12 (80%) |
| Without therapy, n (%) | 4 (33%) | 5 (24%) | 3 (17%) | 3 (20%) |